drugset / Trial / NCT04158817
68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
Phase 0
Completed
8 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NanoMab Technology (UK) Limited · collab
NaSingle-groupOpen-labelDiagnostic
Summary
To evaluate the dosimetry, safety and the detection rate of 68Ga-THP-PSMA PET/CT for identifying the site of prostate cancer metastasis and relapse. It is also to evaluate the association of clinical/pathologic features and 68Ga-THP-PSMA PET/CT detection rate and compare 68Ga-THP-PSMA PET/CT with other imaging procedure.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-THP-PSMA | Diagnostic / imaging agent | 2.11 mbq/kg | Other |
| Background | Non-labeled PSMA | Unknown | 100 ug | Other |